首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1672999

多發性硬化症治療市場按藥物類別、給藥途徑、分銷管道和地區分類

Multiple Sclerosis Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年02月13日 | 出版商:

Coherent Market Insights | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球多發性硬化症治療市場規模估計為 313.9 億美元，預計到 2032 年將達到 418.9 億美元，2025 年至 2032 年的複合年成長率為 4.2%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	313.9億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	4.20％	2032 年金額預測	418.9億美元

數字。 2025 年多發性硬化症治療市場佔有率（按地區分類）

多發性硬化症 (MS) 是一種影響中樞神經系統 (CNS) 的慢性自體免疫疾病。當免疫系統攻擊髓鞘（包圍中樞神經系統 (CNS) 神經纖維的保護鞘）時，就會發生多發性硬化症。結果導致大腦與身體其他部位之間的交流受損。症狀可以從輕微到嚴重，取決於中樞神經系統病變的數量和位置。常見症狀包括疲勞、手腳無力或麻木、失去協調性和平衡性、視力問題和認知障礙。多發性硬化症無法治療方法，但干擾素、醋酸Glatiramer、單株抗體和皮質類固醇等藥物療法可以控制症狀並減緩病情進展。

市場動態

全球多發性硬化症治療市場的成長受到多種因素的推動，例如已開發國家和發展中國家多發性硬化症盛行率的增加、老年人口的增加、大量新型創新多發性硬化症治療方法方法、醫療支出的激增以及報銷計劃的可用性。然而，多發性硬化症治療的高成本可能會阻礙市場的成長。多發性硬化症治療的個人化藥物的出現、聯合治療、輸注療法和多發性硬化症治療的口服藥物的日益採用可以為市場成長提供機會。

研究的主要特點

本報告對全球多發性硬化症治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球多發性硬化症治療市場的主要企業已根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行了分析。

本研究涉及的主要企業包括 Biogen、Novartis、Merck、Sanofi、Teva Pharmaceuticals、Bayer、ACORDA THERAPEUTICS、CELGENE 等。

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

全球多發性硬化症治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員將透過全球多發性硬化症治療市場分析中使用的各種策略矩陣更輕鬆地做出決策。

Biogen Inc.
Novartis AG
Merck KGaA
Sanofi SA
Acorda Therapeutics, Inc.
Teva Pharmaceuticals Industries Ltd.
Bristol-Myers Squibb Company
Bayer AG
Hoffmann-La Roche AG
Viatris Inc.（Mylan NV）
Johnson & Johnson
EMD Serono, Inc.
TG Therapeutics, Inc.
Genentech, Inc.
Celgene Corporation
AbbVie Inc.
Amgen Inc.
UCB SA
山德士（諾華旗下的一個部門）
Ipsen SA

第 9 章分析師建議

興衰
一致的機會地圖

第10章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI1310

Global Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 31.39 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.20%	2032 Value Projection:	USD 41.89 Bn

Figure. Multiple Sclerosis Therapeutics Market Share (%), By Region 2025

Multiple Sclerosis Therapeutics Market - IMG1

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:

This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

Detailed Segmentation-

By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agent
- Others
By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Injection
- Others
By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Biogen Inc.
- Novartis AG
- Merck KGaA
- Sanofi S. A.
- Acorda Therapeutics, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol-Myers Squibb Company
- Bayer AG
- Hoffmann-La Roche AG
- Viatris Inc. (Mylan NV)
- Johnson & Johnson
- EMD Serono, Inc.
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB S.A.
- Sandoz (a Novartis division)
- Ipsen S.A.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Multiple Sclerosis Therapeutics Market, By Drug Class
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Global Multiple Sclerosis Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antineoplastic Agent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Multiple Sclerosis Therapeutics Market, By Region, 2020 - 2032, (USD Bn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S. A.
Acorda Therapeutics, Inc.
Teva Pharmaceuticals Industries Ltd.
Bristol-Myers Squibb Company
Bayer AG
Hoffmann-La Roche AG
Viatris Inc. (Mylan NV)
Johnson & Johnson
EMD Serono, Inc.
TG Therapeutics, Inc.
Genentech, Inc.
Celgene Corporation
AbbVie Inc.
Amgen Inc.
UCB S.A.
Sandoz (a Novartis division)
Ipsen S.A.